Atopix Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 8

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $83M

Atopix General Information

Description

Developer of novel treatments designed for Th2-mediated eosinophilic asthma. The company is developing a novel class of oral anti-allergic medicines, called CRTH2 antagonists, to treat atopic dermatitis, asthma and allergic rhinitis.

Contact Information

Website
www.atopixtherapeutics.com
Formerly Known As
459plus
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Innovation Centre, 99 Park Drive
  • Milton Park, Abingdon
  • Oxon OX14 4RY
  • England, United Kingdom
+44 01235
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Biotechnology
Acquirer
Chiesi Farmaceutici
Vertical(s)
Life Sciences
Corporate Office
  • Innovation Centre, 99 Park Drive
  • Milton Park, Abingdon
  • Oxon OX14 4RY
  • England, United Kingdom
+44 01235

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Atopix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 21-Nov-2016 $83M Completed Clinical Trials - Phase 2
5. Debt - General 03-Jul-2015 Completed Clinical Trials - Phase 2
4. Early Stage VC 01-Jun-2015 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series A) 07-Oct-2014 Completed Clinical Trials - Phase 1
2. Grant 29-May-2013 $2.6M Completed Clinical Trials - Phase 1
1. University Spin-Out 10-Oct-2012 Completed Startup
To view Atopix’s complete valuation and funding history, request access »

Atopix Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A
To view Atopix’s complete cap table history, request access »

Atopix Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel treatments designed for Th2-mediated eosinophilic asthma. The company is developing a novel class of
Drug Discovery
Oxon, United Kingdom
8 As of 2016

Tucson, AZ
 

London, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Atopix Competitors (23)

One of Atopix’s 23 competitors is Aqualung Therapeutics, a Venture Capital-Backed company based in Tucson, AZ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aqualung Therapeutics Venture Capital-Backed Tucson, AZ
hVIVO Formerly VC-backed London, United Kingdom
Amgen Formerly PE-Backed Thousand Oaks, CA
Pliant Therapeutics Formerly VC-backed San Francisco, CA
Insmed Formerly VC-backed Bridgewater, NJ
You’re viewing 5 of 23 competitors. Get the full list »

Atopix Patents

  • 83

    Total Documents Applications and Grants

  • Total Patents Families

  • 50

    Granted

  • 1

    Pending

  • Expiring in next 12 mo

Atopix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201407820-D0 Polymorphic form Inactive 02-May-2014
GB-201407813-D0 Polymorphic form Inactive 02-May-2014
GB-201407807-D0 Polymorphic form Inactive 02-May-2014
US-20170121306-A1 Polymorphic form of [5-fluoro-3-(methyl)-2-methylindol-1-yl]-acetic acid Active 02-May-2014
US-20170057944-A1 Polymorphic form of [5-fluoro-3-(methyl)-2-methylindol-1-yl]-acetic acid Active 02-May-2014 C07D401/06
To view Atopix’s complete patent history, request access »

Atopix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Atopix Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bessemer Venture Partners Venture Capital Minority
MPM BioImpact Venture Capital Minority
Oxford Spin-out Equity Management Venture Capital Minority
Red Abbey Venture Partners Venture Capital Minority
SR One Capital Management Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial

Atopix FAQs

  • When was Atopix founded?

    Atopix was founded in 2012.

  • Where is Atopix headquartered?

    Atopix is headquartered in Oxon, United Kingdom.

  • What is the size of Atopix?

    Atopix has 8 total employees.

  • What industry is Atopix in?

    Atopix’s primary industry is Drug Discovery.

  • Is Atopix a private or public company?

    Atopix is a Private company.

  • What is the current valuation of Atopix?

    The current valuation of Atopix is .

  • What is Atopix’s current revenue?

    The current revenue for Atopix is .

  • How much funding has Atopix raised over time?

    Atopix has raised $17.3M.

  • Who are Atopix’s investors?

    Bessemer Venture Partners, MPM BioImpact, Oxford Spin-out Equity Management, Red Abbey Venture Partners, and SR One Capital Management are 5 of 7 investors who have invested in Atopix.

  • Who are Atopix’s competitors?

    Aqualung Therapeutics, hVIVO, Amgen, Pliant Therapeutics, and Insmed are some of the 23 competitors of Atopix.

  • When was Atopix acquired?

    Atopix was acquired on 21-Nov-2016.

  • Who acquired Atopix?

    Atopix was acquired by Chiesi Farmaceutici.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »